Holen Sie sich die Stockscreener-App
50.82
1.09%
0.55
Handel nachbörslich:
50.75
-0.07
-0.14%
Schlusskurs vom Vortag:
$50.27
Offen:
$50.22
24-Stunden-Volumen:
3.43M
Relative Volume:
0.88
Marktkapitalisierung:
$101.78B
Einnahmen:
$43.93B
Nettoeinkommen (Verlust:
$8.53B
KGV:
13.29
EPS:
3.824
Netto-Cashflow:
$5.74B
1W Leistung:
-3.03%
1M Leistung:
-5.38%
6M Leistung:
-14.05%
1J Leistung:
+28.85%
1-Tages-Spanne:
$49.95
$50.88
1-Wochen-Bereich:
$49.95
$52.21
52-Wochen-Spanne:
$38.63
$61.70
Gsk Plc Adr Stock (GSK) Company Profile
Compare GSK vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
50.82 | 104.07B | 43.93B | 8.53B | 5.74B | 3.824 |
LLY
Lilly Eli Co
|
1,174.61 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
268.04 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
255.48 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
148.35 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.81 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Eingeleitet | Citigroup | Neutral |
| 2026-01-06 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-11-25 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-06-03 | Herabstufung | Berenberg | Buy → Hold |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Neutral |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-11-12 | Herabstufung | Jefferies | Buy → Hold |
| 2024-10-31 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-07-08 | Herabstufung | UBS | Buy → Neutral |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-03-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-02-13 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2024-01-03 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-03-17 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-02-27 | Fortgesetzt | Goldman | Buy |
| 2023-01-03 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-12-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-11-11 | Herabstufung | UBS | Neutral → Sell |
| 2022-09-15 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-21 | Fortgesetzt | Citigroup | Neutral |
| 2022-02-11 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2021-06-24 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2021-03-23 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2021-01-20 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Hold |
| 2020-11-02 | Hochstufung | Liberum | Hold → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-02-12 | Herabstufung | Shore Capital | Hold → Sell |
| 2020-01-16 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2019-12-02 | Eingeleitet | SVB Leerink | Outperform |
| 2019-11-21 | Hochstufung | UBS | Neutral → Buy |
| 2019-10-11 | Hochstufung | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | Fortgesetzt | Citigroup | Neutral |
| 2019-09-03 | Hochstufung | Societe Generale | Sell → Buy |
| 2019-08-13 | Fortgesetzt | JP Morgan | Neutral |
| 2019-06-17 | Fortgesetzt | Morgan Stanley | Underweight |
| 2019-03-08 | Herabstufung | Shore Capital | Buy → Hold |
| 2019-02-22 | Herabstufung | UBS | Buy → Neutral |
| 2019-01-14 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | Fortgesetzt | Jefferies | Buy |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-08-30 | Herabstufung | Liberum | Buy → Hold |
| 2018-04-04 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | Hochstufung | Kepler | Reduce → Hold |
Alle ansehen
Gsk Plc Adr Aktie (GSK) Neueste Nachrichten
Resilient GSK stock steadies after recent earnings beat and sector scrutiny - Ad-hoc-news.de
ETFs Investing in GSK plc Sponsored ADR Stocks - TradingView
GSK Set up for Steady Long-Term Growth As Portfolio and Pipeline Develop - Morningstar
Inside ARMH, STHH and ASMH: Three Semiconductor ADRhedged™ ETFs, and What the Currency Hedge Actually Added - TipRanks
Trump Administration Reportedly Weighs Executive Order on Autism and Vaccines Days After RFK Jr. Hinted At 'Certain Interventions' - Sahm
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of "Hold" by Brokerages - MarketBeat
Weekly Recap: £1.9B savings target and Artemis-011 hits Phase III goal - TradingView
GSK Beats Q2 Earnings & Revenue Estimates, Announces Cost-Saving Plan - TradingView
GSK PLC Sponsored ADR (NYSE:GSK) Announces Quarterly Dividend of $0.45 - MarketBeat
GSK reports $11.28 billion second quarter 2026 revenue - grafa.com
GSK Races To Protect Profits Before Its HIV Blockbuster Faces Generic Rivals - Sahm
GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs Revenue Breakdown – BCBA:GSK - TradingView
Bank of New York Mellon Corp Reduces Holdings in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK: Glaxosmithkline plcADR Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
FDA Greenlights GSK’s First Lung Cancer Drug Ahead of Schedule - Sahm
Free cash flow of GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs – BCBA:GSK.CI - TradingView
PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsight - GlobeNewswire Inc.
Dorsey Wright & Associates Takes Position in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK ends camlipixant programme after CALM-2 miss - grafa.com
Disappointing Data Prompts GSK to Drop Cough Drug Development - Sahm
GSK Stock Quote Price and Forecast - CNN
GSKH ETF Profile: Dividends, Returns (AMEX:GSKH) - TradingView
GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer - TradingView
GSK reports Jemperli rectal cancer trial results - grafa.com
GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership - Sahm
As Biopharma Turns to China, ESG Risks and Geopolitics Remain in Focus - Morningstar
Price to earnings forward of GSK plc Sponsored ADR – MUN:GS70 - TradingView
GSKGSK Plc ADR Latest SEC Filings - Finviz
GS70 Forecast — Price Target — Prediction for 2027 - TradingView
Shareholder in GSK (NYSE: GSK) trims voting stake to 4.96% - Stock Titan
GSK to strengthen oncology pipeline with $10.6B Nuvalent buyout - MSN
Price to earnings forward of GSK plc Sponsored ADR – LS:A3DMHS - TradingView
A3DMHS Forecast — Price Target — Prediction for 2027 - TradingView
GSK plc (GSK) Stock Price, News, Quote & History - Yahoo Finance
GSK (GSK) reports major holder crossing 5% voting rights threshold - Stock Titan
GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs Actuals & Estimates (BCBA:GSKC) - TradingView
Why GSK's Shingrix is reshaping the shingles vaccine market - AD HOC NEWS
GSK PLC (GSK) Stock Price, Trades & News - GuruFocus
GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs - Sahm
Here's Our Take On Theravance Biopharma Inc (NASDAQ:TBPH) and GlaxoSmithKline plc (ADR) (NYSE:GSK)'s Latest Submission - Yahoo Finance
GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorder - TradingView
GSK secures dual US and EU orphan drug status for momelotinib in VEXAS - grafa.com
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal - Sahm
GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent - Sahm
Finanzdaten der Gsk Plc Adr-Aktie (GSK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Gsk Plc Adr-Aktie (GSK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GSK plc | 10% Owner |
Dec 11 '25 |
Buy |
19.00 |
1,470,000 |
27,930,000 |
18,245,691 |
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):